Johnson & Johnson $JNJ Shares Sold by D.B. Root & Company LLC

D.B. Root & Company LLC cut its holdings in Johnson & Johnson (NYSE:JNJ) by 5.9% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,201 shares of the company’s stock after selling 325 shares during the period. D.B. Root & Company LLC’s holdings in Johnson & Johnson were worth $863,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of JNJ. Nuveen LLC acquired a new stake in Johnson & Johnson in the first quarter valued at $1,369,188,000. GAMMA Investing LLC raised its stake in Johnson & Johnson by 24,450.4% in the first quarter. GAMMA Investing LLC now owns 7,215,367 shares of the company’s stock valued at $1,196,596,000 after buying an additional 7,185,977 shares in the last quarter. Bank of New York Mellon Corp raised its stake in Johnson & Johnson by 26.4% in the first quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company’s stock valued at $3,844,580,000 after buying an additional 4,842,582 shares in the last quarter. Janus Henderson Group PLC raised its stake in Johnson & Johnson by 134.5% in the fourth quarter. Janus Henderson Group PLC now owns 7,948,508 shares of the company’s stock valued at $1,149,536,000 after buying an additional 4,559,147 shares in the last quarter. Finally, Northern Trust Corp raised its stake in Johnson & Johnson by 12.3% in the fourth quarter. Northern Trust Corp now owns 30,813,175 shares of the company’s stock valued at $4,456,201,000 after buying an additional 3,363,235 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have issued reports on JNJ shares. Barclays raised their price objective on Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a report on Thursday, July 17th. Royal Bank Of Canada raised their price objective on Johnson & Johnson from $181.00 to $185.00 and gave the stock an “outperform” rating in a report on Thursday, July 17th. Wall Street Zen lowered Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Friday, July 18th. Benchmark raised Johnson & Johnson to a “strong-buy” rating in a report on Thursday, April 24th. Finally, Leerink Partnrs lowered Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, May 13th. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average price target of $176.29.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $178.8990 on Friday. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $180.61. The business’s 50-day moving average price is $163.04 and its 200 day moving average price is $159.05. The firm has a market cap of $430.85 billion, a P/E ratio of 19.13, a P/E/G ratio of 2.28 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The firm had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. During the same quarter last year, the company posted $2.82 earnings per share. The business’s revenue was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, equities research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson’s payout ratio is currently 55.61%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.